Healthcare & Pharmaceuticals

How Johnson & Johnson became the sprawling healthcare giant it is today

2 minute read

A first aid kit made by Johnson & Johnson for sale on a store shelf in Westminster, Colorado April 14, 2009. REUTERS/Rick Wilking

Register now for FREE unlimited access to reuters.com

Nov 12 (Reuters) - Johnson & Johnson (JNJ.N) plans to spin off its consumer health division that sells Listerine and Baby Powder to focus on pharmaceuticals and medical devices in the biggest shake-up in the U.S. company's 135-year history. read more

Here is how J&J got to where it is today.

1886

Register now for FREE unlimited access to reuters.com

Robert Wood Johnson partners with brothers James Wood Johnson and Edward Mead Johnson to found Johnson & Johnson in 1886. It originally focused on ready-to-use sterile surgical dressings.

1894

J&J begins producing Johnson’s Baby Powder.

1918

In response to a global flu pandemic, J&J begins selling a mask designed to limit the spread of the airborne viral illness.

1920

J&J invents Band-Aid and begins marketing it in 1921.

1944

J&J completes its initial public offering and becomes a publicly traded company. It had annual sales of around $95 million at the time, compared to more than $80 billion in 2020.

1959

J&J acquires Tylenol maker McNeil Laboratories.

1961

J&J acquires Janssen Pharmaceuticals, which now makes ADHD drug Concerta and J&J’s COVID-19 vaccine.

1997

The first lawsuit alleging that J&J’s Baby Powder contains cancer-causing asbestos is filed against J&J. Since then, J&J has faced thousands of lawsuits and billions of liabilities and has ceased distributing Baby Powder in the United States and Canada.

1999

J&J acquires Centocor Biotech Inc, maker of Remicade for Crohn's disease, and renames it Janssen Biotech.

2012

Johnson and Johnson acquires orthopedic device maker Synthes for nearly $20 billion to expand its medical product offerings.

2017

J&J acquires Actelion for $30 billion, adding heart disease medicines such as Tracleer to its portfolio.

2020

J&J begins developing a COVID-19 vaccine. It received authorization to begin administering its COVID-19 shot the following year.

https://www.jnj.com/

https://www.asbestos.com/companies/johnson-johnson/

https://www.reuters.com/investigates/special-report/johnsonandjohnson-cancer/

Register now for FREE unlimited access to reuters.com
Reporting by Carl O'Donnell, Editing by Nick Zieminski

Our Standards: The Thomson Reuters Trust Principles.

More from Reuters